<DOC>
	<DOCNO>NCT00424775</DOCNO>
	<brief_summary>The clinical study evaluate safety , tolerability Pharmacokinetics MK0683 combination carboplatin paclitaxel chemotherapy-naive NSCLC patient .</brief_summary>
	<brief_title>A Study Carboplatin + Paclitaxel MK0683 Patients With Chemotherapy-naive Non-Small Cell Lung Cancer ( NSCLC ) ( 0683-066 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Chemotherapynaive patient histologically cytologically diagnose NSCLC stage IIIB ( applicable radical thoracic radiation ) stage IV Patients normal organ function bone marrow function Given radical thoracic radiation NSCLC radiation original lesion within 3 week Any peripheral neuropathy grade 2 Any ascites , pleural effusion pericardiac effusion require treatment Any uncontrolled concomitant illness Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Non-Small Cell Lung Cancer ( NSCLC )</keyword>
</DOC>